Ahead of Pending Studies on PGx-Based Plavix Administration, Is Quest/Scripps CYP2C19 Testing Alliance Premature?
October 28, 2009
Ahead of Pending Studies on PGx-Based Plavix Administration, Is Quest/Scripps CYP2C19 Testing Alliance Premature?
According to Quest, Scripps Health is "the first health system in the US to deploy this genetic testing service for coronary stent patients" receiving Plavix. The testing will initially be available for stent procedure patients presenting to Scripps Green Hospital in San Diego.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - Spartan Bioscience Building Evidence for Point-of-Care PGx Testing to Guide Antiplatelet Therapy
March 13, 2013 / Pharmacogenomics Reporter - Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter - Canadian Team Validates Spartan's Point-of-Care CYP2C19 Test to Personalize Anti-Platelet Treatment
November 30, 2011 / Pharmacogenomics Reporter - Spartan Bioscience's CE-Marked CYP2C19 Test Will Also Be Submitted to the FDA
December 22, 2010 / Pharmacogenomics Reporter